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Summary The distribution and degree of expression of c-yes-I gene product in a variety of cell lines, human
foetal tissues, and adult normal and malignant tissues were examined using immunohistochemical techniques.
A murine monoclonal antibody IB7 raised against a fusion protein consisting of 64 amino acid residues from
the N-terminus of the c-yes-I gene product and bacterial phosphate-binding protein (PBP) was used. At the
ultrastructural level, the c-yes-I gene product recognised by 1B7 was localised in the cytoplasm. Moderate to
strong expression of the c-yes-i gene product was observed in HTIO-80 (fibrosarcoma), IN-1 (malignant
lymphoma), Marcus (glioblastoma), TIG-1-20 (foetal skin fibroblast), proximal tubules of foetal and adult
kidney, one of four breast cancers, one of four colorectal cancers, 14 of 33 head and neck cancers, 13 of 24
renal cancers, three of 19 lung cancers and one of seven stomach cancers. These results were further confirmed
by Western blotting. Histological types showing moderate to strong expression of the c-yes-I gene product
were renal cell carcinoma (13/24) and squamous cell carcinoma (15/38). The fact that the c-yes- gene product
is expressed preferentially in renal cell carcinoma and squamous cell carcinoma may indicate that it plays an
important role.
To date, nine retroviral oncogene products (v-src, v-yes, v-
fgr, v-fps/fes, v-abl, v-ros, v-erbB, v-fms and v-sea) have been
shown to exhibit protein-tyrosine kinase (PTK) activity
(Hayman et al., 1985; Hunter & Cooper, 1985; Kris et al.,
1985; Barbacid et al., 1981). The amino acid sequence res-
ponsible for PTK activity (kinase domain was initially
identified in the v-src protein (Collett et al., 1980; Hunter &
Sefton, 1980; Levinson et al., 1980) and has been shown to
be conserved in the other eight oncogene-encoded proteins
(Hunter, 1985). The kinase domains are also carried in the
receptor proteins for growth factors including epidermal
growth factor (EGF), platelet-derived growth factor (PDGF),
insulin, insulin-like growth factor, and colony-stimulating
factor-I (CSF-1) (Hunter & Cooper, 1985). Recent studies
have shown overlapping of the protein sequences of c-erbB
and c-fms with those of the receptors to EGF and CSF-1,
respectively (Downward et al., 1984; Sherr et al., 1985;
Yamamoto et al., 1983). The cellular counterparts of v-ros,
v-kit and v-sea are also suggested to encode the receptor-type
PTKs (Hunter & Cooper, 1985; Besmer et al., 1986; Yama-
moto et al., 1986; Semba et al., 1985a; Park et al., 1987;
Martin-Zanca et al., 1986; Takahashi et al., 1987; Bargmann
et al., 1986). In addition, cellular oncogenes such as met,
c-erbB-2/neu, trk, and ret encode receptor-like PTKs. Thus,
protein-tyrosine kinases are thought to be important in
regulation of cell growth, and deregulated expression of
receptor-type PTKs may induce cells to undergo neoplastic
transformation in vitro.
The cellular homologues of v-src, v-yes, v-fgr, v-fps/fes and
v-abl, however, encode membrane-associated proteins that
lack transmembrane and extracellular domains. The physio-
logical function of these non-receptor-type PTKs is yet to be
established. To this end, we have analysed the expression of
one of the non-receptor-type PTKs, c-yes-I gene product.
The c-yes gene is the cellular counterpart of the v-yes
oncogene of avian sarcoma virus Y73 (Yoshida et al., 1980;
Kitamura et al., 1982). The human c-yes-I gene is located on
chromosome 18 band 21.3, whereas the human c-yes-2 pseu-
dogene has been shown to be present on chromosome 6
(Semba et al., 1985b). The c-yes-I gene product is a 62 kDa
protein with PTK activity whose entire amino acid sequence
except for the 75 amino acid residues at the amino terminus
is highly conserved when compared to that of pp60vs7c
(Kawai et al., 1980). The 62 kDa c-yes-I gene product p62c-Yes
is reportedly expressed in the brain, retina, liver and kidney.
This protein is associated with and activated by polyoma
virus middle-T antigen, raising the possibility that the
middle-T-p62 complex contributes to transformation by poly-
oma virus. However, little is known about the involvement of
c-yes-I in naturally occurring human malignancies except
that the gene is amplified in primary gastric cancer (Seki et
al., 1988). As an initial step toward elucidating the function
and transforming potential of c-yes-I gene product, it seems
to be of vital importance to examine the distribution of the
gene product in a variety of normal and malignant tissues. In
this study, we analysed the distribution and expression of the
c-yes gene product in various cell lines and tissues using a
murine monoclonal antibody reactive with the human c-yes-1
gene product.
Materials and methods
Cell lines and tissues
Nine cell lines, BeWo (choriocarcinoma), HeLa (uterine cer-
vix carcinoma), HT1080 (fibrosarcoma), K562 (chronic mye-
logenous leukaemia), KB (epipharyngeal carcinoma), KD
(foetal lip fibroblast), Marcus (glioblastoma), T98G (glioblas-
toma) and TIG-1-20 (foetal skin fibroblast) were obtained
from the Japanese Cell Resource Bank (JRCB, Tokyo,
Japan). IN-I (malignant lymphoma) was established in our
laboratory (Sugawara et al., 1990). All the lines were main-
tained in RPMI 1640 medium containing 10% heat-activated
foetal calf serum and passaged once a week.
Human foetal tissues were obtained from six foetal cad-
avers at gestational ages of 9-23 weeks, which were autop-
sied within an hour after death. Human adult non-malignant
and malignant tissues were obtained from surgical specimens
and biopsy samples. Normal tissues were also prepared from
the same surgical specimens. Malignant tissues included four
breast cancers, four colorectal cancers, 33 head and neck
cancers, 19 lung cancers, 24 renal cancers, seven stomach
cancers and ten urinary bladder cancers.
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The specimens were placed in Tissue-Tek O.C.T. com-
pound (Miles Laboratories, Naperville, IL) and snap-frozen
in n-hexane precooled with dry ice-acetone immediately after
surgical extirpation and stored at -70°C until further pro-
cessing.
Preparation and characterisation ofmonoclonal antibody, 1B7
A murine monoclonal antibody (MAb), 1B7, reactive with
the human c-yes-I gene product was used. The subclass of
MAb 1B7 is IgG2a. The preparation and characterisation of
MAb 1B7 have been described in detail elsewhere (Sukegawa
et al., 1990). Briefly, a fusion protein consisting of 64 amino
acid residues from the N-terminus c-yes-I protein and bac-
terial phosphate-binding protein (PBP) was expressed in
Escherichia coli. Female Balb/c mice, 4 weeks old, were
immunised with the fusion protein intraperitoneally several
times. After somatic cell hybridisation, the hybrid cells were
screened in HAT medium and the hybridoma supernatants
were assayed for their anti-PBP-c-yes-1 fusion protein
activity byt ELISA. The hybridoma lines producing antibody
reactive with the fusion protein but not with PBP were
subcloned by limiting dilution using a feeder layer of
peritoneal macrophages and finally 1B7 specific to the c-yes-I
protein, was found.
Immunostaining
The avidin-biotin-peroxidase (ABC-PO) and avidin-biotin-
glucose oxidase (ABC-GO) methods were performed with
Vectastain ABC kits (Standard, Vector Laboratories, Burlin-
game, CA). The staining procedure was based upon a
method described elsewhere (Hsu et al., 1981; Sugawara et
al., 1988).
Non-immunised mouse myeloma IgG (1.0 mg ml', Sigma)
at the same concentration as MAb 1B7 was applied to every
section as a negative control. Frozen sections were also
stained with hematoxylin and eosin for histological observa-
tion. The histological diagnosis was confirmed by reviewing
formalin-fixed paraffin-embedded, hematoxylin and eosin-
stained sections taken from the same surgical specimens.
Cell tysate preparation
Cell lines and tissues showing elevated expression of the
c-yes-I protein, together with a pleomorphic adenoma of the
parotid gland and a tonsil specimen without immunocyto-
chemical expression of the c-yes-I protein were minced briefly
(max 10 min) in cell lysis buffer containing 1% Triton X-100,
1.0% sodium deoxycholate, 0.1% sodium dodecyl sulfate
(SDS), 0.15 M NaCl, and 2 mM phenyl methyl sulfonyl
fluoride (PMSF) in 50 mM Tris-HCI (pH 7.4). The lysed cells
or tissues were centrifuged at 10,000 g for 15 min, and the
supernatants were collected.
SDS-PAGE and western blotting
The extracts were diluted in buffer containing 0.5 M Tris-HCI
(pH 6.8), 10% SDS, 50% glycerol, 5% 2-p-mercaptoethanol,
and 0.05% bromophenol blue (1:4), boiled for 4 min, and
loaded onto 7.5% SDS-polyacrylamide gel containing a 4%
stacking gel (Laemmli, 1970) for 30 min at a constant 200 V.
Immediately after electrophoresis, the proteins were transfer-
red to a nitrocellulose membrane for 4 h at 50 V, (Towbin et
al., 1979; Mitani et al., 1988) after which nitrocellulose was
transferred to a plastic tray and blocked with 2% skim milk
at 4°C for 12 h. Then the membrane was rinsed in washing
buffer (0.05% Tween 20 in PBS) eight times and reacted
sequentially with (i) 1B7 (1:100-diluted, 500 tl) for 2 h and
(ii) '251I-labelled anti-mouse IgG whole antibody (Amersham
Laboratories, Amersham, Buckinghamshire, England, 1:20-
diluted) at room temperature followed by rinsing with wash-
ing buffer eight times, respectively. The nitrocellulose sheet
was dried completely and placed on X-ray film.
Immunoelectron microscopy
To examine the localisation of the c-yes-I gene product
recognised by MAb 1B7, immunoelectron microscopy was
carried out. IN-1 cells (1 x 107ml-') in suspension were first
treated with periodate-lysine-paraformaldehyde (PLP) for
45 min. Then they were treated with MAb 1B7 (50 Ig ml-')
at 4°C for 12 h. A negative control was prepared by incubat-
ing the cells with normal mouse immunoglobulins (1:50-
diluted, Sigma) overnight. They were then cultured with
biotinylated horse anti-mouse IgGs (1:50-diluted, Vector) for
3 h at 4°C. After rinsing with PBS, they were incubated with
the diluted ABC reagent for 1 h at room temperature. The
final colour reaction was achieved by incubating the cells
with 0.1% H202 and 0.05 M Tris buffer (pH 7.2) for 5 min.
The cells were post-fixed dehydrated with a grade ethanol
series and embedded in Epon 812 resin. After polymerisation
at 60°C for 48 h, ultrathin sections were prepared with an
ULTRACUT E (C. Reichert Optische Werke AG, Wien,
Austria). Semi-thin sections were also prepared for optical
microscopy. The ultrathin sections were subsequently stained
with uranyl acetate for 10 min and examined with an electron
microscope (IOOC, Japan Electron Optical Laboratories,
Tokyo, Japan) (Sugawara et al., 1988).
Results
Immunohistochemistry
Various staining patterns were observed. Among the cell lines
(Table I), HT1080, IN-1, Marcus and TIG-1-20 cells were
stained postively. Figure 1 shows the positive staining for
MAB 1B7 observed on TIG-1-20 cells.
Among the foetal tissues (Table II), epithelial cells of renal
proximal tubules, hematopoietic cells in the bone marrow
and spleen and epithelial cells in the stomach were stained
positively. Figure 1 shows the positive staining for MAb 1B7
observed on epithelial cells of the renal proximal tubules in
foetal and adult kidney, and also negative staining.
Among the adult normal tissues (Table III), only epithelial
cells of the renal proximal tubules were stained positively.
Among the malignant tissues (Table IV), positive to intensely
positive staining for MAb 1B7 was observed in one of four
breast cancers, one of four colorectal cancers, 14 of 33 head
and neck cancers, 13 of 24 renal cancers, three of 19 lung
cancers, and one of seven stomach cancers. Figures 2 and 3
show positive staining with MAb 1B7 observed on lung
cancer (squamous cell carcinoma), renal cancer (renal cell
carcinoma) and negative controls.
Then we examined the relationship between histological
type and positive immunostaining of malignant tissues. As
shown in Table V, 13 of 24 renal cell carcinomas, 15 of 38
squamous cell carcinomas and four of 23 adenocarcinomas
were stained positively, but none of ten transitional cell
carcinomas showed positive staining. Thirty-three out of 101
malignant tissues were positively stained with MAb 1B7.
Table I Expression ofc-yes-I gene product in cell lines
Staining
Cell line intensity Origin ofcell line
BeWo - Choriocarcinoma
HeLa - Uterine cervix carcinoma
HT1080 + Fibrosarcoma
IN-1 + Malignant lymphoma
K562 - Chronic myelogenous leukaemia
KB - Epipharyngeal carcinoma
KD - Fibroblast (foetal lip)
Marcus + Glioblastoma
T98g - Glioblastoma
TIG-1-20 + Fibroblast (foetal skin)
'Staining intensity: -; negative, +; positive.510 K. SUGAWARA et al.
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Figure 1 Immunostaining ofc-yes-I gene product on TIG-1-20 cells by MAb 1B7 A, negative control (non-immune mouse serum
was used instead of MAb IB7) B, proximal renal tubules (foetal kidney) C, negative control D, proximal renal tubules (adult
kidney) E, negative control F, x 400. ABC-PO and ABC-GO methods.
Western blot analysis
In order to confirm that the antigens on cells and tissues
recognised by MAb 1B7 were compatible with the 62 kD
c-yes-I gene product, immunoblotting was performed. The
lanes in Figure 4 represent the solubilised proteins from
TIG-1-20 cells, foetal kidney, maxillary sinus cancer, meso-
pharyngeal cancer, pleomorphic adenoma of the parotid
gland, lung cancer, renal cancer and tonsil after SDS-PAGE
and immunoblotting with MAb 1B7. The pleomorphic aden-
oma of the parotid gland and the tonsil specimens were not
immunostained. Bands corresponding to a molecular mass of
ca 62 kDa were observed in lanes 1-4, 6 and 7.
Immunoelectron microscopy
c-yes-I gene product was located focally in the cytoplasm of
IN-1 cells. It was not associated with any organelles (Figure
5).
Discussion
This communication describes the distribution and degree of
expression of the protein encoded by the c-yes-i gene, one of
the tyrosine kinase family, in cells and tissues. From the data
obtained, the following points were raised, which warrant
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Table II Expression and distribution ofc-yes-I geneproduct in foetal
tissuesa
Gestational age in weeks (case no.)a
Tissue 9(1) 11(2) 14(2) 23(1) Distribution
Adrenal - -
Bone marrow - +(1/2) Hematopoietic cells
Cartilage (rib)
Cerebellum
Cerebrum
Colorectum
Duodenum
Oesophagus
Myocardium
Kidney - +(2/2) + Epithelial cells renal
proximal to
Liver
Lung
Lymph node
Pancreas
Placenta
Spleen +(1/2) Hematopoietic cells
Bone marrow
(femoral region)
Spinal cord
Stomach - +(1/2) Epithelial cells
Thymus
'Staining intensity:-; negative, +; positive. + Numbers in paren-
thesis indicate the numbers offoetuses examined.
Table III Expression and distribution of c-yes-I gene product in
normal tissues
Staining
Tissue intensit/a Distribution
Adrenal -(3)b
Colorectum -(3)
Duodenum -(1)
Kidney -(3/3)
Stomach -(5) Epithelial cells of
Tonsil -(1) proximal renal tubules
Parotid gland -(5)
Thyroid gland -(3)
Oesophagus -(2)
aStaining intensity: -; negative, +; positive. bNumbers in paren-
theses indicate the numbers of specimens examined.
Table IV Expression ofc-yes-I gene product in malignant tissues
Staining intensity'
Primary site - + + + Positivity
Breast 3 1 0 1/4
Colorectum 3 1 0 1/4
Head and neck 19 8 6 14/33
Kidney 11 8 5 13/24
Lung 16 1 2 3/19
Stomach 6 0 1 1/7
Urinary bladder 10 0 0 0/10
Total 68 19 14 33/101
aStaining intensity:-; negative, +; positive if less than 50% of the
tissue was stained, + +; intensely positive if most of the tissue was
stained.
further comment.
First, the 64 amino-terminal amino acid sequence used as
an immunogen is unique to the c-yes protein and shows little
homology to the corresponding sequences of other src-family
kinases (Sukegawa et al., 1987; Yamamoto et al., 1989).
Therefore, no cross-reactivities of the MAb with related gene
products such as the c-src, c-fgr and fyn proteins were
expected and this was further confirmed experimentally by
immunoblotting experiments (data not shown) and in situ
hybridisation experiments (Sugawara et al., 1989).
Second, c-yes-i protein was found to be expressed notably
in the epithelial cells of foetal and adult proximal renal
tubules, suggesting that in the kidney, the c-yes-I gene pro-
duct may play some physiological role in cell growth and
metabolism.
Figure 2 Immunostaining ofc-yes-I gene product on lung squa-
mous cell carcinoma. MAb 1B7 A, negative control B, x 400.
ABC-PO method.
i- fqTw S
Figure 3 Immunostaining of c-yes-I gene product on renal cell
carcinoma. MAbIoB7 A, negative control B x 400. ABC-PO
method.
Table V Relationship between histological type and expression of
c-yes-I gene product in malignant tissues
Staining intensity/
Histological type - + + + Positivity
Adenocarcinoma 19 3 1 4/23 Adenoid cystic carcinoma 2 1 0 1/3 Mucoepidermoid carcinoma 1 0 0 0/1 Papillary carcinoma 2 0 0 0/2 Renal cell carcinoma 11 6 7 13/24 Squamous cell carcinoma 23 6 9 15/38 Transitional cell carcinoma 10 0 0 0/10 Total 68 16 17 0/101
aStaining intensity: -; negative, +; positive if less then 50% ofthe
tissue was stained, + +; intensely positive if most of the tissues was
stained.
Third, overexpression of c-yes-I gene product evaluated
immunohistochemically and by Western blotting was observ-
ed at higher incidence in renal cell carcinoma (13/24) and
squamous cell carcinoma (15/38) than in adenocarcinoma
(4/23) and transitional cell carcinoma (0/10), indicating that
the biochemical properties of c-yes-I protein in carcino-
genesis may differ from those of receptor-type protein encoded by the c-erbB-2 gene, which has been demonstrated
to show overexpression of its product and/or amplification in
a significant proportion of human adenocarcinomas (Yokota
et al., 1986; Mori et al., 1987; Van De Vijver et al., 1987; Zhou et al., 1987; Barnes et al., 1988). c-yes-I protein was
hardly detected in squamous epithelia, but it was present in
the epithelial cells of the proximal renal tubules of the
kidney. Therefore, it is suggested that the c-yes-I gene pro-512 K. SUGAWARA et al.
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Figure 4 Western blot analysis of solubilised proteins from TIG-
1-20 cells (1), foetal kidney (2), maximillary sinus cancer (3),
mesopharyngeal cancer (4), pleomorphic adenoma of the parotid
gland (5), lung cancer (6), renal cancer (7), and tonsil (8). Each
solubilised protein was subjected to SDS-PAGE under reducing
conditions prior to blotting and then reacted with MAb 1B7.
Arrow (-*) shows the band corresponding to a molecular mass of
ca 61 kDa. The band is not recognised in lane 5 or 8.
duct may play a role in malignant transformation of squa-
mous cell carcinoma and renal cell carcinoma. Among the
cell lines tested, c-yes-I protein was expressed in HT1080
(fibrosarcoma), IN-1 (malignant lymphoma), Marcus (glio-
blastoma) and TIG-1-20 (foetal skin fibroblast), suggesting
that the c-yes-I protein may be involved in either the patho-
genesis of several kinds of malignancy or in cellular growth
and differentiation, or both.
Fourth, at the ultrastructural level, c-yes-I gene product
was localised in the cytoplasm. There has been no detailed
report on the localisation of the c-yes-I gene product.
Finally, the expression of c-yes-I protein in foetal hemato-
poietic cells of the bone marrow and spleen suggests that
c-yes-I gene product may play a role in the differentiation of
some kinds of cell. In fact it was recently demonstrated that
non-receptor-type kinases encoded by the src gene or yes-
related oncogenes are associated with not only cell growth
but also cell differentiation (Gee et al., 1986; Golden et al.,
1986; Marth et al., 1987; Ziegler et al., 1987).
It has been suggested that a number of oncogenes may be
implicated in tumourigenesis, but there are no data available
at present to enable their roles in tumourigenesis to be
assigned individual genes, and few of them have proved to be
of diagnostic value. Further examination of protein expres-
sion in a large series of surgical specimens may provide clues
to the function of the c-yes-I gene product. Also, the rela-
tionship between protein expression and the clinical features
of various malignancies including 5-year survival, recurrence,
degree of invasiveness, or metastases should be further anal-
ysed.
The authors are greatly indebted to Ms I. Kataoka and Mr
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